Narrowing Pipelines Lower Profits Of Japan's Big Three Pharmaceutical Outfits
This article was originally published in PharmAsia News
Thinning drug pipelines of Japan's major pharmaceutical companies began to have an effect on company net profits during the first quarter of the fiscal year. Daiichi Sankyo, Eisai and Takeda each reported a profit decline, with part of the problem due to the cost of recent acquisitions and/or a fluctuating yen. But Takeda also got hit with a delay in U.S. approval of a major diabetes drug and Eisai saw declining sales for its major Alzheimer's drug. All three companies, however, maintained their projected earnings through next March. (Click here for more - a subscription may be required
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.